# Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

> **NCT03667820** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 41 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Osimertinib
- **RADIATION:** SABR

## Key facts

- **NCT ID:** NCT03667820
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-26
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03667820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03667820, "Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03667820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*